QuantX Biosciences has raised US$85m in Series B funding to develop two oral small-molecule drug candidates.
The financing will back a STAT6 inhibitor and an IL-17 inhibitor, oral small molecules designed for immunology and inflammation diseases.
The raise brings QuantX’s total funding to US$130m since its founding in 2022.
Alongside its two lead programmes, the money will support the discovery of additional oral therapies for the immunology and inflammation disease space.
QuantX’s computational drug discovery platform combines physics-based and statistical modelling to generate oral small-molecule therapeutic candidates.
The company was founded in 2022 by Wayne Tang and Yax Sun and was incubated by OrbiMed and Creacion Ventures.
Wei Li, a founding partner of Creacion and currently serving as QuantX’s interim chief executive, said: “In only three years, we’ve assembled a world-class team that’s been successful in not only discovering multiple, new, first-in-class small molecule candidates for diseases with large patient populations, but have also advanced these to IND-enabling studies.”
IND-enabling studies are preclinical studies required before a drug can be tested in human clinical trials.
The Series B was co-led by Sanofi Ventures and LAV, with other investors including Hongshan also participating.
David Wang, partner and senior managing director at OrbiMed, said: “The combination of QuantX’s ability to deliver best-in-class assets and the speed by which they’re able to advance these programmes makes for a unique value proposition across a variety of therapeutic indications.”
